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Summary DNA amplification seems to be particularly frequent in human breast tumours and has been
associated with cancer evolution and aggressiveness. Recent data indicate that new events should be added to
the list, such as the amplifications at chromosome 20q13 or the MDM2 gene. The present work aimed at
determining the incidence and clinicopathological signification of these amplifications in a large series of breast
and ovarian tumours. We tested 1371 breast and 179 ovarian tumours by Southern blotting and observed
amplification of 20q13 in 5.4% breast and 2.8% ovarian carcinomas, whereas MDM2 was found amplified in
5.3% and 3.8% of breast and ovarian tumours respectively. MDM2 RNA expression levels were analysed in a
subset of 57 breast tumours and overexpression was observed in 4/57 (7%) of the tumours. Elevated expression
levels coincided with amplification of the gene. In breast cancer, 20q13 and MDM2 amplifications seem to
define subsets of aggressive tumours. Indeed, 20q13 was correlated to axillary nodal involvement and occurred
preferentially in younger patients (<50 years). Furthermore, 20q13 correlated, as did MDM2 amplification, to
aneuploidy. In parallel, we had also tested our tumour DNAs for amplification of CCNDJ, ERBB-2 and MYC,
which made it possible to test for correlations with 20q13 or MDM2 amplifications. Whereas 20q13 showed a
very strong correlation to CCNDI amplification, that of MDM2 was prevalent in MYC-amplified tumours.
Interestingly, 20q13 and MDM2 amplifications showed some degree of correlation to each other, which may
possibly be owing to the fact that both events occurred preferentially in aneuploid tumours. In ovarian cancer,
no statistically significant correlation was observed. However, 20q13 amplification occurred preferentially in
stage 3 tumours and MDM2 was correlated to ERBB-2 amplification. This may suggest that in ovarian
tumours also, 20q13 and MDM2 amplifications occur in late or aggressive cancers.
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Among the multiple genetic alterations occurring during
breast cancer development, DNA amplification seems of
particular importance. Based on conventional molecular
genetic methods, amplification of genes or chromosomal
sites in breast cancer was detected at the MYC (8q24),
ERBB-2 (17ql2), CCNDI (1lql3), FGFRI/FLG (8pl2),
FGFR2 (lOq26) loci (Escot et al., 1986; Slamon et al., 1989;
Lammie et al., 1991; Adnane et al., 1991). However, recent
methodological development in molecular cytogenetics, such
as comparative genomic hybridisation (CGH) or chromo-
some microdissection, have demonstrated that the number of
amplified regions was larger, and have allowed the discovery
of new, yet unsuspected, amplification sites in breast cancer
(Kallioniemi et al., 1994; Guan et al., 1994), as well as other
cancers (Kallioniemi et al., 1993). Amplification sites that can
be added to the list concern lq21, lq31-q32, 6p, lOq22,
16pl -pl3, 19q13 and 20q13 (Kallioniemi et al., 1994; Guan
et al., 1994). Amplification at 20q13 seemed particularly
prevalent, since it was detected in 40% of breast cancer cell
lines and 18% of primary breast tumours tested by CGH
(Kallioniemi et al., 1994; Guan et al., 1994). Identity of the
gene (genes) remains to be determined and a number of
possible candidates (SRC, TOPOI, ADA) as well as other
genes mapping in this region have already been excluded
(Tanner et al., 1994). The amplified region has been scaled
down to a minimum of 1.5 Mb mapping at 20ql3.2 (Tanner
et al., 1994). Work by Tanner et al. (1995) suggested that the
20q13 amplification may define a subset of aggressive breast
tumours.
The mdm2 gene was originally identified as the selected
oncogene within a double-minute chromosome in a NIH/3T3
variant. Amplification of mdm2 was shown to confer
tumorigenic potential to these cells (Fakharzadeh et al.,
1991). The p95-MDM2 protein turned out to be a major
cellular partner of the p53 anti-oncogene (Momand et al.,
1992; Oliner et al., 1993) and was shown to counteract its
growth-suppressing properties (Finlay, 1993). The human
MDM2 gene has been assigned to chromosome 12ql3, in a
region that is frequently rearranged or bearing cytogenetic
markers of amplification in soft-tissue sarcomas (Stenman et
al., 1993; Meltzer et al., 1991). The discovery that the MDM2
gene was amplified and overexpressed in a sizeable fraction of
these sarcomas (Oliner et al., 1992) strengthened the
hypothesis that MDM2 activation (by means of DNA
amplification or deregulated expression) could be an
alternative mechanism to p53 mutation (Leach et al., 1993).
This led to a number of studies searching for DNA
amplification and/or overexpression of MDM2 in human
primary cancers. Whereas MDM2 amplification was con-
firmed in human sarcomas with differences among histologi-
cal subgroups (Florenes et al., 1994; Cordon Cardo et al.,
1994; Patterson et al., 1994), its activation did not seem to be
a prevalent event in carcinomas and most haematological
malignancies (Waber et al., 1993; Habuchi et al., 1994;
Preudhomme et al., 1993; Quesnel et al., 1994a). In breast
cancer, amplification of the MDM2 gene was observed in
about 5% of the tumours (Quesnel et al., 1994b; McCann et
al., 1995) and overexpression of the protein in 7% (McCann
et al., 1995). No firm association with clinicopathological
parameters could be determined.
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We have gathered a large collection of breast tumour
DNAs (> 1500), which were digested by EcoRI and organised
on blotting membranes, allowing a rapid and homogeneous
screening for DNA amplification. For most of these tumour
DNAs, we could also collect the complete set of connected
clinicopathological data. Having this material at hand, we
were interested in verifying the incidence of and the
correlations connected to the amplifications at both 20q13
and mdm2 in our breast cancer collection. We also tested a
series of ovarian tumours, in order to verify whether these
amplifications were shared by both cancer types. In this
work, we present the analysis of 1371 breast and 179 ovarian
tumour DNAs.
Material and methods
Tumour samples and clinical material
Breast and ovarian tumour samples were collected at surgery
in the Val d'Aurelle-Paul Lamarque Cancer Centre in
Montpellier (France) or at the First Department of
Gynecology and Obstetrics of the General Hospital in
Vienna (Austria) and the Department of Gynecological
Oncology at the University Hospital of Turin (Italy).
Samples were snap frozen in liquid nitrogen and stored at
-80°C before processing. All clinical data were registered,
compiled and standardised according to the WHO histologi-
cal typing of breast and ovarian tumours. Detailed
descriptions of the breast and ovarian tumour series are
given in Tables I and II respectively.
Preparation of DNA and blots
Tumour DNAs were prepared as previously described
(Adnane et al., 1989). DNAs (4 ,ug) were digested with
EcoRI and dispensed in 96-well microtitre plates. Blots were
prepared at the Genethon (Evry/Seine, France) on automated
Table I Description of the breast tumour cohort analysed
Characteristics n %
Histological typesa
IDC 954 69.6
DCIS 15 1.1
Comedo carcinoma 12 0.9
ILC 178 13.0
Inflammatory carcinoma 15 1.1
IAC 156 11.3
Other invasive carcinoma 41 3.0
Neoadjuvant therapyb 61 4.4
Axillary node invasion
0 462 49.8
1 -3 232 25
>3 233 25.1
SBR grade
1 62 6.7
2 458 49.3
3 409 44
ER> 10 fmol mg-' protein 917 67.7
ER< 10 fmol mg-l protein 438 32.3
PgR> 10 fmol mg-' protein 772 57.0
Pgr < 10 fmol mg-I protein 582 43.0
Age <50 years 307 28.2
Age>50 years 780 71.8
Total number of tumours analysed 1371
Tumours were classified according to commonly used disease
parameters. aHistological types were determined according to the
WHO guidelines. IDC, invasive ductal carcinoma; ILC, invasive
lobular carcinoma; DCIS, ductal in situ carcinoma; IAC, breast
carcinoma whose differentiation level did not allow further determina-
tion; otherinvasive carcinoma includescolloid, papillary andmedullary
carcinomas. bNeoadjuvant therapy includes the tumours which have
been surgically removed after hormonal or chemotherapy.
Table II Description of the ovarian tumours analysed
Clinicopathological parameters
Tumour type
Serous
Mucinous
Clear-cell carcinoma
Endometrioid
Other
Tumour stage
1
2
3
4
Tumour grade
1
2
3
4
n
84
11
9
16
59
40
10
72
26
16
25
50
6
%/
47.0
6.0
5.0
9.0
33.0
27.1
6.8
48.6
17.6
16.5
42.3
51.5
6.2
Total analysed 179
Allclassifications were determined according to theWHOguidelines.
blotting robots (Mark II prototypes from Bertin, France).
Hybridisation, washing and autoradiography were as
described (Adnane et al., 1989).
Isolation of RNA andpreparation of Northern blots
Isolation oftotal RNA was performed according to a method
combining the procedure described by Chomczynski and
Sacchi (1987) and the caesium chloride cushion extraction
method of Sambrook et al. (1989).
Quantification ofhybridisation signals
This was done using the Bioimage Image Analysis system
from Millipore. Briefly, it was performed as follows: digital
images of the autoradiograms were acquired using a CCD
camera and images were scanned and quantified. Density
ratios of the target probe and the reference probes were
determined in each lane. Ratios were normalised by
calculating a mean value of several normal DNAs. Ratios
exceeding 2 were considered as amplified. For probes, such as
MDM2, which revealed five bands, signals were quantified on
the three most prominent bands and amplification was taken
into account only when the results from all three bands were
concordant.
Probes
The probe used in this study to assess amplification at 20q13
corresponds to a 1.3 kb EcoRI subclone of the RMC 20C001
cosmid clone, which has been shown to map to this region
(Tanner et al., 1994). The MDM2 probe was a 900 bp human
cDNA fragment cloned in our laboratory. The ERBB-2/
NEU, MOS and MYCN probes were as previously described
(Adnane et al., 1991). The pBird probe corresponds to an
anonymous human cDNA probe of 800 bp cloned in our
laboratory which, upon hybridisation on tumour DNAs,
turned out to accurately reflect the quantity of DNA loaded
in each lane.
Statistics and data analysis
Clinical and molecular data associated with each patient were
pooled in a computer-assisted data base, which we routinely
run under Paradox for DOS from Borland software.
Statistical analyses were performed with the Epilnfo 3.0
software package from CDC (Atlanta, GA, USA) for
classical x2. Tests for data stratification were done with the
Knowledge Seeker 3.0 from Angoss Software (Hawkins and
Kass, 1982).20q13 and MDM2 amplifications in aggressive breast ovarian cancer
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Results
20q13 and MDM2 amplifications in sporadic breast cancer
The gene(s) involved at 20ql3 remains to be identified, but
Tanner et al. (1994) isolated a series of cosmid clones from
this region, which were mapped according to the amplicon.
Cosmid RMC20C0O1 was found to be the closest to the core
of the amplification unit and was a good candidate to test for
DNA amplification on Southern blots. We subcloned a
C", C' LO) CD 'u
CDX O'XC')'XU)LflLf
n c n CM C') M - q-
-9.0 kb
-5.0
-4.4
-3.5
-2.0
MDM2
1.3 kb EcoRI fragment, devoid of any repetitive sequences,
and used this to probe our collection of Southern blots. On
EcoRI blots, this probe revealed, as expected, a 1.3 kb band
(Figure 1). Amplification at 20q13 was detected in 74/1371
tumours (5.4%) (Table III) and amplification levels were in
the range 2- to 5-fold in 64%, 5- to 8-fold in 31% and 8- to
15-fold in 5% of the amplified cases.
MDM2 gene amplification was tested using a 900 bp
HindIII cDNA probe. On our EcoRI blots it revealed five
bands of approximately 2.0, 3.5, 4.4, 5.0 and 9.0 kb (Figure
1). The MDM2 gene was found amplified in 71/1341 (5.3%)
tumour DNAs (Table III). Levels of amplification were in the
range 2- to 5-fold in 66%, 5- to 8-fold in 27% and 8- to 20-
fold in 7% of the amplified cases. Maximum levels of
amplification tended to be higher for MDM2 than those
observed with the 20q13 probe (Figure 1).
In parallel with the 20q13 and the MDM2 probes, we
tested our tumour DNA collection with probes to ERBB-2/
NEU, CCNDI and MYC, which are known to undergo gene
amplification. This allowed us to calibrate our tumour cohort
with regard to known anomalies. As shown in Table III,
ERBB-2/NEU, CCNDJ and MYC were found amplified in
14.6%, 11.1% and 12.2% of tumours respectively. These
numbers indicate that MDM2 and 20q13 amplifications were
inferior by a factor 2 to 3 to those of ERBB-2/NEU, CCNDI
and MYC.
MDM2 RNA expression in breast cancer
MDM2 RNA expression levels were investigated in 57
tumours for which biological material was available in
sufficient quantities to allow RNA extraction. As shown in
Figure 2, most tumours showed basal levels of MDM2 RNA.
Overexpression could be observed in (7%) 4/57 tested
tumours and was concomitant with DNA amplification
(Figure 2).
Correlations with disease parameters
Statistical analyses were performed to determine whether
amplification at 20q13 was correlated to a specific disease
parameter in breast cancer. Amplification at 20q13 showed a
Table Ill Incidence of DNA amplification
cancer
in breast and ovarian
Amplified loci Breast tumours Ovarian tumours
20q13 5.4% (74/1371) 2.8% (5/179)
MDM2 5.3% (71/1341) 3.8% (6/158)
ERBB-2/NEU 14.6% (195/1333) 9.5% (17/179)
MYC 12.2% (88/720) 19.7% (31/157)
CCNDI 11.1% (146/1309) 3.1% (4/130)
20q13
I
pBird
-1.3 kb
-3.5 kb
Figure 1 Examples of DNA amplification detected with the
20q13 and the MDM2 probes. Each lane corresponds to a tumour
DNA (at the top are patient numbers). Probes used are indicated
at the bottom of the autoradiogram; sizes in kb are shown on the
right. Several probes were routinely used as DNA loading
standards; signals shown here were obtained with MYCN and
pBird. The latter probe is an anonymous human cDNA cloned in
our laboratory, the signal ofwhich strictly reflected the loading in
each lane.
v
It) C') CD 0 co u0) c) 0
o
)
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r- 0) X
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Figure 2 Examples of MDM2 RNA expression levels tested on
eight breast tumours. The tumour indicated by an arrowhead
presented an amplification at the DNA level. Each lane was
loaded with lOjg of total RNA, separated on 1% agarose gel
containing 250mm formaldehyde and blotted on a charged nylon
membrane. Blots were sequentially hybridised with the MDM2
and GAPDH probes.
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statistically significant correlation with axillary nodal
involvement (N+ tumours) and, interestingly, with loss of
normal DNA ploidy (Table IV). However, DNA ploidy
results were only available for a restricted set of tumours,
thus limiting the significance of this observation. Finally, we
found a correlation with the age of the patient. Amplification
at 20q13 seems prevalent in patients below 50 years (Table
IV).
MDM2 amplification was found to correlate with the
presence of oestrogen receptors (ER+), but not with
progesterone receptor positivity (PR'). Furthermore, we
noted a correlation with loss of normal ploidy (Table IV).
We investigated whether levels of amplification correlated
with parameters of disease aggressiveness. Neither for the
MDM2 gene nor the locus at 20q13 did we observe
significant variations according to tumour grade, nodal
invasion, receptor status or ploidy.
Groups of co-amplifications
We investigated whether 20q13 and MDM2 amplifications
occurred as independent events or could be associated with
other amplification events in our breast tumour cohort. The
statistical analysis revealed that amplification at 20q13 was
highly associated with that of CCNDJ (P-value= 10-5),
whereas MDM2 amplification correlated to that of MYC
(Table V). Interestingly, we also observed a correlation
linking 20ql3 and MDM2 amplifications (Table V).
20q13 and MDM2 amplifications in ovarian tumours
In ovarian tumours, 20ql3 and MDM2 amplifications were
also observed, albeit at a lower incidence (2.8% and 3.8%
respectively) than in breast cancer (Table III). These numbers
should be considered with reference to incidences found for
ERBB-2, MYC and CCNDI amplifications (9.5%, 19.7%
and 3.1% respectively) (Table III).
Statistical analysis did not reveal any significant clinico-
pathological correlation. However, some trends were
observed. All the tumours presenting an amplification at
20q13 were of stage 3, suggesting a trend towards evolved
ovarian cancer, whereas MDM2 amplification seemed
restricted to serous adenocarcinoma (data not shown).
Whereas amplification of MDM2 was correlated to that of
ERBB-2 (P=0.008), 20q13 sequences were not preferentially
co-amplified with any of the other loci tested. On the
contrary, we observed an apparent exclusion between 20q13
and MYC or MDM2 amplifications. Indeed, tumours
harbouring amplified MYC or MDM2 genes never presented
amplified 20q13 sequences.
Discussion
We have gathered a large collection of human breast and
ovarian tumour DNAs. DNAs were digested by EcoRI and
organised on blotting membranes ready to hybridise.
Table IV Clinicopathological correlations observed in breast tumours with 20q13 and MDM2
amplification
20qJ3 MDM2
Clinicopathological amplification amplification
parameters n % P-value n % P-value
SBR grade
1 2/62 3.2 3/60 5.0
2 25/458 5.5 24/444 5.4
3 24/409 5.9 NS 27/403 6.7 NS
Lymph node statusa
N- 18/462 3.9 28/452 6.2
-N+ 32/465 6.9 0.042 25/457 5.5 NS
Hormonal receptorsb
ER- 18/432 4.2 NS 14/424 3.3
ER+ 53/917 5.8 56/895 6.25 0.02
PR- 30/574 5.2 NS 26/562 4.7
PR+ 40/772 5.2 43/754 5.7 NS
Diploid DNA content 3/71 4.2 0/74 0.0
Non-diploid DNA 10/74 13.5 0.048 7/74 9.5 0.008
Age< 50 years 25/307 8.1 16/305 5.2
Age> 50 years 37/780 4.7 0.03 42/766 5.5 NS
Total 74/1371 5.4 71/1341 5.3
aAxillary lymph node status was divided into twosubclasses: absence ofmetastatic node (N-) and one
or more invaded nodes (N+). bTumours were considered oestrogen (ER) or progesterone receptor (PR)
positive when measured levels exceeded 10 fmol mg-'ofprotein. DNA ploidy was classified as follows:
diploid, tumourswith 2Npics or tumours with 2N+ aproliferationpic at4N; non-diploid, aneuploid and
tetraploid tumours. NS, not significant.
Table V Co-amplifications observed in the cohort of breast tumour DNAs
Genes or loci 20ql3 MDM2
analysed Status amplification % P-value amplification % P-value
MDM2 Amplified 8/71 11.3 0.03 NA NA NA
Non-amplified 66/1270 5.2
ERBB-2/NEU Amplified 13/195 6.6 NS 14/195 7.2 NS
Non-amplified 61/1138 5.4 57/1137 5.0
MYC Amplified 3/32 9.4 NS 5/32 15.6 0.007
Non-amplified 18/321 5.6 14/320 4.4
CCND1 Amplified 15/101 14.9 10 8/101 7.9 NS
Non-amplified 39/905 4.3 45/887 5.1
20q13 amplification was correlated to that ofCCND1 and, to a lesser extent to that ofMDM2. MDM2 amplification
correlated to MYC amplification and to 20q13. NS, not significant.
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Southern blots were prepared on automated blotting robots
yielding very reproducible results. This allowed a rapid
screening with probes to 20q13 and MDM2, as well as
ERBB-2, MYC and CCNDJ.
Our interest in 20q13 amplification lies in the fact that,
among the new amplification sites detected in breast cancer
by CGH, it was observed in 40% of analysed cell lines and
18% of primary tumours (Kallioniemi et al., 1994).
Furthermore, sequences mapping at 20q13 were found to
be part of 5/16 marker chromosomes analysed by chromo-
some microdissection in nine breast tumour cell lines (Guan
et al., 1994). Hence, our aim was to test for the
clinicopathological significance of this amplification event
on a large series of primary breast carcinomas, and we
further wanted to verify whether it could also occur (and how
frequently) in ovarian cancer.
Concerning MDM2, albeit its role as a negative effector of
p53 (Finlay, 1993), data reported did not support the idea of
it being implicated in a large portion of breast tumours
(Quesnel et al., 1994b; McCann et al., 1995). This justified
our interest in testing for the incidence of MDM2
amplification and its clinicopathological significance on our
tumour DNA collection.
In our series of breast tumours 20q13 and MDM2 were
found amplified in 5.4% and 5.3% of DNAs respectively.
These numbers are two to three times lower than those
observed with ERBB-2, MYC or CCNDI amplification in the
same set of tumour DNAs, thus suggesting amplification of
20q13 or MDM2 does not represent prevalent events in
breast cancer. It is, however, to be noted that in 30-40% of
the tumours showing an MDM2 or a 20q13 amplification,
amplification levels exceeded 5-fold, thus suggesting a selected
event. The fact that genes like ERBB-3 or N-MYC, tested in
the same breast tumour panel, only very rarely showed
variations in copy numbers (1/1371), may come as a further
indication of the significance of MDM2 and/or 20q13
amplification in breast cancer. Moreover, MDM2 gene
amplification could always be associated with RNA
expression in the subset of breast tumours tested for RNA
expression. Finally, both amplifications seemed to character-
ise subpopulations of aggressive breast tumours, as testified
by correlations with nodal involvement (20q13) and loss of
normal ploidy. This association with aneuploidy suggests that
these amplifications occur preferentially in tumours bearing
destabilised genomes. This may, in the case of MDM2, result
from the role of the p95-MDM2 protein, which, over-
expressed, could interfere with the normal function of the p53
protein and counteract the integrity of the G, and G2 cell
cycle checkpoints.
The correlation between 20q13 amplification and pre-
menopausal patients was somewhat intriguing. One possible
hypothesis could be that amplification at 20q13 defined a
subset of breast tumours occurring in premenopausal patients
and prone to axillary lymph node invasion. This may, in fact,
be the case since, in patients below 50 years of age, the risk of
axillary nodal invasion is significantly increased in 20q13-
amplified tumours (76.5% of N+ with 20q13 amplification,
49.5% without amplification, P-value=0.03). Work by
Tanner et al. (1995) and Isola et al. (1995) strongly suggests
that amplification of 20q13 sequences is related to breast
tumour aggressiveness and shortened disease-free survival.
Interestingly, the difference in disease-free survival was
particularly significant in node-negative patients. This may
be a difference between our data and those of Tanner et al.
(1995), who observed, as we did, a correlation with DNA
ploidy, but not nodal involvement. This may be attributable
to differences in the composition of each tumour cohort.
CCNDJ and 20q13 amplifications seem highly correlated
events as shown by the observed P-value of l0-'. About 30%
of the 20q13-amplified tumours harboured a CCNDI gene
amplification as well. By contrast, 15% of CCNDJ-amplified
tumours showed co-amplification of 20ql3. This could
suggest that 20ql3 amplification defines a subgroup among
breast tumours with an amplified CCNDI gene. Further
indications on genetic alterations associated with 20q13
amplification should come from a focused CGH study on a
subset of such breast tumours.
MDM2 amplification showed a correlation with that of
MYC. MYC amplification has been defined as a marker of
disease aggressiveness and this association, in addition to the
correlation with aneuploidy, further suggests that MDM2 is
preferentially amplified in evolved breast tumours. The
correlation observed between 20q13 and MDM2 amplifica-
tions is interesting and may, in fact, be due to the fact that
both events occurred preferentially in aneuploid tumours.
Further investigation on larger numbers may be required to
get a better insight into its meaning.
In ovarian cancer, 20q13 and MDM2 amplifications were
less frequent than in breast cancer. These numbers suggest
that these amplifications do not represent most prevalent
events in this tumour type. However, 20q13 amplification
showed a trend of association with stage 3, and MDM2
amplification seemed restricted to serous adenocarcinoma.
In conclusion, although 20q13 and MDM2 amplifications
did not represent prevalent events in our series of breast and
ovarian tumours, both seemed to occur preferentially in
evolved and aggressive tumours. Numbers and correlations
with other known amplifications may suggest that 20q13 and
MDM2 amplifications represent secondary events occurring
during tumour evolution.
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